Pillar 1 - FTO (new thread), page-820

Hey @Jdmoney

Thanks for sharing. The paper has shown that a reduced FTO content of osteoblasts in mice showed a negative outcome. Although, looking more closely at the study that you have shown, it appears that the researchers were investigating the role of FTO in growth of postnatal mice. Postnatal meaning after childbirth and more specifically, the study was looking from 3 to 30 weeks.



Evidence is pretty clear that FTO plays a key role in the development of body tissues and I think the researchers were moreso determining what happens if FTO is lacking through the growth period of a mammals life - a mouse in this instance. Thus, it highlights the caution that might need to be taken when using a potent FTO inhibitor in children or young adults. However, I highly doubt that a small period of inhibiting FTO for the sake of cancer would have much influence on long-term bone health in humans.

--

The screenshot I have included below is from an article evaluating the regulatory role of RNA N6-Methyladenosine modification in bone biology and osteoporosis (1). They have an entire section on FTO and based on the information that I have highlighted, evidence is accumulating that supports the contention that FTO negatively impacts on osteoporosis. This is not taking into account the role of writer inhibition and the impact that has on downstream genes and proteins that modify risk to osteoporosis.



Hope this helps.

1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965011/pdf/fendo-10-00911.pdf